Retinitis Pigmentosa News and Research

RSS
Retinitis pigmentosa (RP) is the name given to a group of inherited eye diseases that affect the retina (the light-sensitive part of the eye). RP causes the breakdown of photoreceptor cells (cells in the retina that detect light). Photoreceptor cells capture and process light helping us to see. As these cells breakdown and die, patients experience progressive vision loss. The most common feature of all forms of RP is a gradual breakdown of rods (retinal cells that detect dim light) and cones (retinal cells that detect light and color). Most forms of RP first cause the breakdown of rod cells. These forms of RP, sometimes called rod-cone dystrophy, usually begin with night blindness. Night blindness is somewhat like the experience normally sighted individuals encounter when entering a dark movie theatre on a bright, sunny day. However, patients with RP cannot adjust well to dark and dimly lit environments.
Australian researchers hope to switch on sight with new gene therapy

Australian researchers hope to switch on sight with new gene therapy

No papers, no care: Disabled migrants seek help through lawsuit, activism

No papers, no care: Disabled migrants seek help through lawsuit, activism

New technology makes it easier to diagnose neurodegenerative diseases

New technology makes it easier to diagnose neurodegenerative diseases

New printable device could restore sight to blind people

New printable device could restore sight to blind people

Gene therapy may offer a new approach to preserving vision in people with retinitis pigmentosa

Gene therapy may offer a new approach to preserving vision in people with retinitis pigmentosa

Advanced computer model could lead to improvements in 'bionic eye' technology

Advanced computer model could lead to improvements in 'bionic eye' technology

Fight for Sight funds research to explore gene editing as treatment for inherited retinal diseases

Fight for Sight funds research to explore gene editing as treatment for inherited retinal diseases

UC San Diego researchers launch clinical trial to test gene therapy for Alzheimer’s disease

UC San Diego researchers launch clinical trial to test gene therapy for Alzheimer’s disease

Study finds locations of early prion protein accumulation in the eye

Study finds locations of early prion protein accumulation in the eye

Newly developed light-sensing protein restores vision in blind mice

Newly developed light-sensing protein restores vision in blind mice

Researchers design new ocular insert to administer antioxidants in the eye

Researchers design new ocular insert to administer antioxidants in the eye

First pathoconnectome shows how eye disease alters retinal circuitry

First pathoconnectome shows how eye disease alters retinal circuitry

Study reveals how people with retinal degenerative disease can maintain night vision

Study reveals how people with retinal degenerative disease can maintain night vision

Doctors with disabilities call for a paradigm shift to make medical education, profession more inclusive

Doctors with disabilities call for a paradigm shift to make medical education, profession more inclusive

New cell injection technique could help reverse forms of vision loss

New cell injection technique could help reverse forms of vision loss

New nanoparticle-based artificial retina prosthesis restores vision in blind rats

New nanoparticle-based artificial retina prosthesis restores vision in blind rats

Researchers develop artificial liquid retinal prosthesis to counteract the effects of eye disorders

Researchers develop artificial liquid retinal prosthesis to counteract the effects of eye disorders

Hungarian physician to receive the Körber Prize for European Science 2020

Hungarian physician to receive the Körber Prize for European Science 2020

Researchers question the mechanism of retinitis pigmentosa

Researchers question the mechanism of retinitis pigmentosa

Santen Pharmaceutical and jCyte conclude an exclusive licensing contract in Japan, Asia and Europe for the jCell therapy programme for retinitis pigmentosa

Santen Pharmaceutical and jCyte conclude an exclusive licensing contract in Japan, Asia and Europe for the jCell therapy programme for retinitis pigmentosa

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.